Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.

Exclusion Criteria

• •Prior treatment for irresectable stage III or stage IV melanoma with BRAF/MEK inhibitors.
• •Presence of progressive/symptomatic brain metastases at baseline.
• •WHO performance score ≥ 2.
• •Adjuvant treatment with anti-PD1 immunotherapy received within the last 6 months.
• •Patients undergoing experimental treatments or therapies.
• •Presence of any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study.
• •Unwillingness or inability to comply with study and follow-up procedures.